Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis. The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
For 125 years, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines to meet serious unmet medical needs in cancer and other diseases. Incyte’s drug discovery activities were initiated in 2002 on the belief that investments in innovation create value. Incyte remains committed to the rigorous pursuit of R&D excellence to improve the lives of patients, make a difference in health care, and build sustainable value for its stakeholders.
The Company strives to discover and develop first-in-class and best-in-class medicine and is advancing a diverse portfolio of large and small molecules comprised of 18 development candidates against 14 different molecular targets.
Headquartered in Wilmington, Delaware, Incyte Corporation has offices in Switzerland, nine other European countries and Japan. For more information, visit www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/Incyte.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2015, it generated 2,208 million euros in net sales, of which 58% came from its international business and 57% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,000 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2015, Pierre Fabre dedicated almost 200 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.
With its brands, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Pierre Fabre Health Care, Pierre Fabre Oral Care and Naturactive, Pierre Fabre is the market leader in France for skin care, hair care and oral care products sold in pharmacies and drugstores. Marketed globally, Eau Thermale Avène is the leading dermo-cosmetics brand in Europe and in Asia. In oncology, Pierre Fabre generates over 90% of its revenue outside France.
Pierre Fabre is mostly owned (86%) by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees.